Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Neurofilament light chain as a tool for assessing disease activity and treatment response in Multiple Sclerosis].

Fortschritte der Neurologie-Psychiatrie·2026
Same author

Assessing Progression Independent of Relapse Activity in Multiple Sclerosis Using a Patient-Reported Disability Measure and Self-Administered Neuroperformance Outcomes.

Annals of neurology·2026
Same author

Are Traditional Registries Becoming Obsolete in the Modern Digital Health Ecosystem?

Journal of medical Internet research·2026
Same author

Exploring attitudes and acceptance of artificial intelligence in multiple sclerosis from the patient perspective.

PLOS digital health·2026
Same author

Brain age gap in multiple sclerosis: associated with disability but independent of serum biomarkers.

Therapeutic advances in neurological disorders·2026
Same author

Adherence to risk minimization measures for alemtuzumab use in multiple sclerosis: a drug utilization study in four European countries.

Therapeutic advances in neurological disorders·2026

Related Experiment Video

Updated: Jun 20, 2026

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

58.6K

A Novel, Integrative Approach for Evaluating Progression in Multiple Sclerosis: Development of a Scoring Algorithm.

Chloe Tolley1, Daniela Piani-Meier2, Sarah Bentley1

  • 1Adelphi Values Ltd, Macclesfield, United Kingdom.

JMIR Medical Informatics
|April 15, 2020
PubMed
Summary

A new tool aids in evaluating patients at risk of multiple sclerosis (MS) progression to secondary progressive MS (SPMS). It identifies key predictors like age, disease activity, and mobility, offering a consistent evaluation method.

Keywords:
SPMSalgorithmdisease progressionmultiple sclerosis, relapsing-remittingtool

More Related Videos

A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS
06:49

A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS

Published on: October 6, 2015

20.6K
Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis
08:11

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Published on: November 14, 2016

11.4K

Related Experiment Videos

Last Updated: Jun 20, 2026

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

58.6K
A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS
06:49

A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS

Published on: October 6, 2015

20.6K
Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis
08:11

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Published on: November 14, 2016

11.4K

Area of Science:

  • Neurology
  • Clinical Research
  • Patient Outcomes

Background:

  • An unmet need exists for tools to assess multiple sclerosis (MS) patients at risk of progressing to secondary progressive MS (SPMS).
  • A novel tool has been developed to evaluate early signs of MS progression.
  • Initial development involved mixed methods, including regression analysis and qualitative research.

Purpose of the Study:

  • To develop a scoring algorithm for a new MS progression evaluation tool.
  • Utilized both quantitative and qualitative research methodologies.

Main Methods:

  • Developed a draft scoring algorithm using quantitative analysis of real-world data and qualitative analysis from physician interviews.
  • Employed multiple logistic regression with physician- and patient-reported data.
  • Conducted ranking and weighting exercises with 8 experienced neurologists.

Main Results:

  • Physician-reported predictors of SPMS progression included age, MS disease activity, and Expanded Disability Status Scale score.
  • Patient-reported predictors included age, mobility, and self-care.
  • Physicians identified symptom stability/worsening, intermittent/persistent symptoms, and ambulatory/cognitive symptoms as most important.

Conclusions:

  • Confirms the need for a consistent tool to evaluate early signs of SPMS progression.
  • The scoring algorithm development triangulated data from multiple sources.
  • Identified subtle signs beyond obvious lower limb impairment as relevant indicators of progressive disease.